RA
DERM icon

Rosalind Advisors’s Journey Medical DERM Stock Holding History

Rosalind Advisors’s Portfolio DERM Stock Details DERM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-105,917
Closed -$598K – 45
2024
Q3 		$598K Sell
105,917
-8,215
-7% -$42.3K 0.38% 28
2024
Q2 		$644K Buy
+114,132
New +$470K 0.5% 32

Other funds holding DERM

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $12.5B AUM 18.49% 1-Year Est. Return

Rosalind Advisors's DERM Position: Q4 2024 in Review

Rosalind Advisors sold out of Journey Medical (DERM) in Q4 2024, closing a stake of 105,917 shares — an estimated $598K sold.

Rosalind Advisors first reported a position in DERM in Q2 2024 and held it in 2 quarters. The position peaked at $644K in Q2 2024. 37 funds tracked by Wall St. Rank hold DERM as of Q4 2024.

  • Rosalind Advisors reported no remaining Journey Medical position as of Q4 2024 after selling out during the quarter.
  • Rosalind Advisors sold 105,917 Journey Medical shares in Q4 2024, an estimated $598K.
  • Rosalind Advisors first reported a position in Journey Medical in Q2 2024 and held it in 2 quarters.
  • Rosalind Advisors's Journey Medical position peaked at $644K in Q2 2024.
  • 37 funds tracked by Wall St. Rank held Journey Medical as of Q4 2024.

Based on Rosalind Advisors's 13F filing for Q4 2024, filed 11 Feb 2025.